Has Chasity Torrence received payments from drug or device companies?

Yes. Drug and device makers reported $833,971 in general payments to Chasity Torrence across 1,356 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Chasity Torrence did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Chasity Torrence come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Chasity Torrence

Psychiatry · Whitfield, MSNPI 1407110554

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $701,479 of the $833,971 with a category attached, or 84.1%. Neurocrine Biosciences, Inc. accounts for 60.2% of it on its own, with 18 other manufacturers making up the rest. 2025 is the largest year on record at $237,868, 2.9 times the $82,729 reported in 2019. Among psychiatry clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$833,971in general payments, 2019–2025

Across 1,356 payments — averaging $615.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Neurocrine Biosciences, Inc.$502K
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$242K
E.r. Squibb & Sons, L.L.C.$45K
Otsuka America Pharmaceutical, Inc.$38K
Alkermes, Inc.$2K
Teva Pharmaceuticals USA, Inc.$1K
plus $3K from 13 others

What the payments were for

Consulting fees$43,6455%
Speaking & faculty fees$701,47984%
Travel & lodging$64,4418%
Food & beverage$24,2893%
Education$1170%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Neurocrine Biosciences, Inc.	642	$501,822
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	270	$242,422
E.r. Squibb & Sons, L.L.C.	77	$45,379
Otsuka America Pharmaceutical, Inc.	74	$38,344
Alkermes, Inc.	66	$1,531
Teva Pharmaceuticals USA, Inc.	61	$1,260
Johnson & Johnson	38	$863
Lundbeck LLC	43	$689
AbbVie(2 entities)	33	$545
Vanda Pharmaceuticals Inc.	16	$310
Greenwich Biosciences, Inc.	4	$175
Avanir Pharmaceuticals, Inc.	9	$162
Indivior Inc.	8	$149
Sunovion Pharmaceuticals Inc.	9	$135
Bioxcel Therapeutics, Inc.	1	$97
Axsome Therapeutics, Inc.	2	$35
UCB, Inc.	1	$19
Otsuka Pharmaceutical Development & Commercialization, Inc.	1	$18
Supernus Pharmaceuticals, Inc.	1	$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$833,971 in reported general payments places this provider in the 95th percentile of 219 psychiatry providers in Mississippi.

See all psychiatry providers in Mississippi →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Abilify AsimtufiiAripiprazole	18	$104,204
UzedyRisperidone	17	$92,643
VraylarCariprazine Hcl	11	$16,281
Haloperidol Decanoate	37	$2,733
Clozapine	16	$1,254
Divalproex Sodium	33	$1,134
Quetiapine Fumarate	55	$786
Olanzapine	37	$694
Divalproex Sodium ErDivalproex Sodium	17	$600
Trazodone Hcl	57	$466
Hydroxyzine Pamoate	43	$453
Trihexyphenidyl Hcl	11	$365
Sertraline Hcl	47	$338
Benztropine Mesylate	31	$335
Aripiprazole	18	$329

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Asimtufii	$38,344	$104,20418 claims
Teva Pharmaceuticals USA, Inc.Uzedy	$1,260	$92,64317 claims
AbbVieVraylar	$545	$16,28111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 219 psychiatry providers in Mississippi.

Other psychiatry in Whitfield

Andrew ForetWhitfield$8K
Kirtida DesaiWhitfield$5K
Holden LeeWhitfield$5K
Deewan BulchandaniWhitfield$4K
Salaahuddin DakhlallaWhitfield$4K
Hannah RichardWhitfield$4K
Tyler MenziesWhitfield$3K
Patrick Fitz-GeraldWhitfield$3K
Mariah BohlWhitfield$3K
Gerri WilsonWhitfield$3K

See the full list for Mississippi →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →